Literature DB >> 3489521

Macrophage tumoricidal activity induced by human C-reactive protein.

K Zahedi, R F Mortensen.   

Abstract

Purified C-reactive protein (CRP), the prototypical acute phase reactant of humans, activated inflammatory mouse macrophages to a tumoricidal state. The activation by CRP was not due to small amounts of contaminating lipopolysaccharide. CRP at 10 micrograms/ml induced significant tumoricidal capacity in resident macrophages; the mouse macrophage cell lines PU5 1.8, RAW 264.7, and J774; as well as elicited macrophages from two lipopolysaccharide nonresponder strains, C3H/HeJ and C57BL/10Sc. Macrophages obtained from bone marrow-derived monocytes grown in vitro and exudate macrophages depleted of T-cells were also readily activated by microgram/ml amounts of CRP. Removal of CRP from culture medium using anti-CRP antibodies or phosphorylcholine-agarose beads abrogated the induction of tumoricidal activity. CRP acted independently of both lymphokines and lipopolysaccharide. Therefore, CRP may serve as a physiologically relevant macrophage activator, contributing to the heightened nonspecific host resistance associated with the early stages of a systemic inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489521

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  C-reactive protein, inflammation, and innate immunity.

Authors:  R F Mortensen
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Defined chemically cross-linked oligomers of human C-reactive protein: characterization and reactivity with the complement system.

Authors:  H Jiang; T F Lint; H Gewurz
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

3.  Degradation of rat C-reactive protein by macrophages.

Authors:  A Nagpurkar; D Hunt; C Y Yang; S Mookerjea
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

4.  C-reactive protein and alpha 1-acid glycoprotein levels in dogs infected with Ehrlichia canis.

Authors:  Y Rikihisa; S Yamamoto; I Kwak; Z Iqbal; G Kociba; J Mott; W Chichanasiriwithaya
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

5.  C-reactive protein protects against preerythrocytic stages of malaria.

Authors:  S Pied; A Nussler; M Pontent; F Miltgen; H Matile; P H Lambert; D Mazier
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

Review 6.  A hypothesis resolving the apparently disparate activities of native and altered forms of human C-reactive protein.

Authors:  M J Shields
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 7.  C-Reactive Protein and Cancer: Interpreting the Differential Bioactivities of Its Pentameric and Monomeric, Modified Isoforms.

Authors:  Lawrence A Potempa; Ibraheem M Rajab; Margaret E Olson; Peter C Hart
Journal:  Front Immunol       Date:  2021-09-06       Impact factor: 7.561

Review 8.  Immune status for monitoring and treatment of bladder cancer.

Authors:  Shen Pan; Shijie Li; Yunhong Zhan; Xiaonan Chen; Ming Sun; Xuefeng Liu; Bin Wu; Zhenhua Li; Bitian Liu
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

9.  Investigation of the biological and anti-cancer properties of ellagic acid-encapsulated nano-sized metalla-cages.

Authors:  Abhishek Dubey; Dae Won Park; Jung Eun Kwon; Yong Joon Jeong; Taegeun Kim; Inhye Kim; Se Chan Kang; Ki-Whan Chi
Journal:  Int J Nanomedicine       Date:  2015-09-02

Review 10.  An overview on human serum lectins.

Authors:  S Beulaja Manikandan; R Manikandan; M Arumugam; P Mullainadhan
Journal:  Heliyon       Date:  2020-08-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.